Cheuk Sing Medical Lists on HKEX, Daily Turnover Reaches Approximately HK$203 Million

*Image source: HKEX

DentalGoodNews | On February 6, 2026, Cheuk Sing Medical Holdings Limited (hereinafter referred to as "Cheuk Sing Medical") officially listed on the Main Board of the Hong Kong Stock Exchange, with a final offering price of HK$59.90 per share. According to the allotment results announcement, the Hong Kong public offering received 147,844 valid applications, with a subscription level reaching 2,730.73 times. In terms of stock performance, Cheuk Sing Medical shares opened at HK$81.00 per share and closed at HK$67.90 per share on the day. The intraday high reached HK$90.85 per share, with a low of HK$65.15 per share. The daily turnover was approximately HK$203 million, with a trading volume of 2.42 million shares.

*Image source: Cheuk Sing Medical share allotment results

According to previous DentalGoodNews reports, Cheuk Sing Medical passed the Main Board listing hearing of the Hong Kong Stock Exchange in December 2025. This global offering consisted of 4.75 million shares, of which 475,000 shares (10%) were allocated to the Hong Kong public offering and 4.275 million shares (90%) to the international offering. The international offering attracted 211 placees with a subscription level of 5.79 times. Based on the final offering price, the company's net proceeds from fundraising amount to approximately HK$209 million.

*Image source: Cheuk Sing Medical share allotment results

In terms of cornerstone investors, four institutions collectively subscribed for 1.5004 million shares, accounting for 31.59% of the total offered shares. Among them, Health Vision Hong Kong Limited subscribed for 727,200 shares, Kingmed Diagnostics (Hong Kong) Limited subscribed for 386,600 shares, Mininglamp Technology subscribed for 257,800 shares, and Galaxy Dynasty Limited subscribed for 128,900 shares.

*Image source: Cheuk Sing Medical share allotment results

According to relevant disclosures, the controlling shareholder of Cheuk Sing Medical Holdings Limited consists of Mr. Wang Zhiyuan (Cheuk Sing Ho) and his parties acting in concert. Mr. Wang Zhiyuan, through personal shareholdings and contractual arrangements, together with Distinct Partners I Limited and other entities, constitutes the company's controlling shareholder and concert party group. Immediately following the completion of the global offering, Mr. Wang Zhiyuan directly or indirectly controls voting rights attached to an aggregate of 19.821532 million shares, representing approximately 30.79% of the company's issued share capital after listing (assuming the over-allotment option is not exercised).

The announcement also disclosed that Mr. Wang Zhiyuan and his parties acting in concert have made lock-up commitments regarding their shareholdings. Among them, Mr. Wang Zhiyuan's 11.283 million shares are subject to a 30-month lock-up period from the listing date, Distinct Partners I Limited's 2.64025 million shares are subject to an 18-month lock-up period, and the shares held by other parties acting in concert are subject to lock-up periods ranging from 12 months.

*Image source: Cheuk Sing Medical post-hearing information pack

According to the post-hearing information pack, Cheuk Sing Medical was established in 2012 and is positioned in the mid-to-high-end comprehensive medical services market. According to Frost & Sullivan reports, based on 2024 revenue, the company is China's third-largest private mid-to-high-end comprehensive medical service provider, with a market share of 2.0%. Its revenue primarily comes from physical medical services. In the first eight months of 2025, its dental business generated revenue of RMB 114 million, accounting for 17.8% of physical medical service revenue. As of August 31, 2025, the company operates 19 medical service institutions across 11 cities in China, including 17 clinics and 2 hospitals. The physician team consists of 387 full-time doctors with an average of approximately 15 years of practice experience.